Medicortex was granted a Finnish patent related to the detection of tissue damage

Medicortex’s tissue damage diagnostics patent “Method of detecting tissue damage” was granted in Finland (FI patent No. 130428). The patent covers testing of carbohydrates specific to tissue damage in urine of patients for detection of orthopaedic injury. This is a unique approach since the current detection methods are using radiation and they require arriving to a medical facility, trained personnel, and depend on equipment availability, all at high cost. The diagnostic kit to be developed by Medicortex will enable self-testing in order to determine the need to go to a hospital to be further analysed.

Medicortex has once again received confirmation of its strength in patent protecting the innovations and new technologies it has developed in-house by its experienced research team.

Dr. Harel, CEO of Medicortex says: “The diagnostic kit Medicortex is developing will enable a person to test him/herself using a non-invasive body fluid sample such as urine or saliva in order to determine if an actual tissue damage has occurred and if so, he/she will definitely need to go to a hospital for further analysis. This kit can help reduce dramatically the cost and time needed for diagnosis of such injuries.”

The company has applied for a research grant to further advance the R&D project related to this invention.

Medicortex has currently a funding round ending on 31^st of August with beneficial terms of one free option for each share purchased. More information about the current share issue is available at: https://www.medicortex.fi/eng/investors/

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors, which may result in that the company’s actual future results, operations, achievements, and performance of the sector may differ significantly from the results, operations, achievements, and performance specifically or indirectly indicated in such forward-looking statements. Such risks, uncertainties and other important factors include, among other things, risks related to the implementation of the company’s strategy and availability of financing, general economic and market situation, and other risks. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.